Literature DB >> 18973734

Pain management in gout.

Brian S Kirby1, Joan C McTigue, N Lawrence Edwards.   

Abstract

Gout is currently the most common form of inflammatory arthritis in men. The overall incidence of gout has increased rapidly in the past 20 years. Clinicians in all fields are likely to experience a patient with acute gout in their career. Uncontrolled gout and hyperuricemia can lead to joint destruction and significant morbidity. Fortunately, these diseases can be readily treated and long-term sequelae can be prevented. Recent advances in understanding the role of the innate immune system in acute gout have provided new treatment options. This article addresses the epidemiology, inflammatory pathophysiology, pain management techniques (including recent advances), and treatment of the underlying disease itself.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973734     DOI: 10.1007/s11916-008-0071-9

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  26 in total

1.  Colchicine analogs in the treatment of acute gout.

Authors:  S L WALLACE
Journal:  Arthritis Rheum       Date:  1959-10

2.  Anakinra for the treatment of neonatal-onset multisystem inflammatory disease.

Authors:  Hal M Hoffman; Gary S Firestein
Journal:  Nat Clin Pract Rheumatol       Date:  2006-12

3.  Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation.

Authors:  Ru Liu-Bryan; Peter Scott; Anya Sydlaske; David M Rose; Robert Terkeltaub
Journal:  Arthritis Rheum       Date:  2005-09

Review 4.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

6.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

7.  Prevalence of the metabolic syndrome in individuals with hyperuricemia.

Authors:  Hyon K Choi; Earl S Ford
Journal:  Am J Med       Date:  2007-05       Impact factor: 4.965

8.  Ultrasonographic measurement of tophi as an outcome measure for chronic gout.

Authors:  Fernando Perez-Ruiz; Iñaki Martin; Begoña Canteli
Journal:  J Rheumatol       Date:  2007-07-15       Impact factor: 4.666

9.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study.

Authors:  Hyon K Choi; Gary Curhan
Journal:  BMJ       Date:  2008-01-31

10.  Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.

Authors:  A Maccagno; E Di Giorgio; A Romanowicz
Journal:  Curr Med Res Opin       Date:  1991       Impact factor: 2.580

View more
  1 in total

1.  Generalized pain hypersensitivity and associated factors in gout.

Authors:  Peter M Ten Klooster; Jannis T Kraiss; Rik Munters; Harald E Vonkeman
Journal:  Rheumatology (Oxford)       Date:  2022-08-30       Impact factor: 7.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.